India IPO Grey Market Premiums Show NSE Decline After 32% Drop

India IPO grey market premiums showed uneven pre-listing sentiment, with National Stock Exchange of India’s GMP declining nearly 32% from Rs 218 on September 11 to around Rs 148 by 3 p.m. on September 17. At the same time, several recent mainboard and SME issues produced sharply different listing-day outcomes.

What happened to National Stock Exchange of India’s GMP?

National Stock Exchange of India’s GMP weakened materially over the reported one-week period, despite a modest recovery on the day its IPO opened. The premium was quoted at Rs 218 per share on September 11, before falling to Rs 125 on September 17. It later recovered to around Rs 148 by 3 p.m., but remained well below the prior week’s level.

IPO GMPs are unofficial indicators of the premium that investors may be willing to pay over an issue price before listing. The reported movement in National Stock Exchange of India’s premium shows that these indications can change quickly even before a public issue completes its subscription process. The context does not provide a specific reason for the fall.

Which India IPO GMPs are drawing attention in November?

IPO GMPs are varied across issues, with Crystal Crop Protection indicating a 16-18% potential premium while other recent issues carried far smaller or larger implied gains. Crystal Crop Protection’s Rs 455.5 crore IPO is scheduled to open on November 18, with a price band of Rs 259-272 per share.

Among recently discussed SME issues, Bombay Coated and Special Steels had a reported GMP of Rs 8 against an issue-price ceiling of Rs 82, which pointed to about a 10% premium. Vedant Poly Fabs was discussed with an indicated grey-market price around Rs 95 against an issue price of Rs 94. BLS Polymers was reported to have a Rs 68 GMP, implying a potential gain of about 45%, though such an indication was explicitly not guaranteed.

How did recent India IPO listings compare with expectations?

Recent India IPO outcomes were dispersed, ranging from a 99.5% gain for Maxwell Engineering Solutions to an 8.4% fall for Zetwerk Manufacturing Businesses. The tracked listing-day-close data also showed Vedant Poly Fabs down 5.0%, despite its grey-market indication of a marginal gain over the Rs 94 issue price.

Bombay Coated and Special Steels closed 15.6% above its issue price after its reported 10% GMP, while BLS Polymers was up 79.2% against the issue price after a reported potential gain of about 45%. These comparisons do not establish a predictive relationship, but they show that the eventual market outcome can differ substantially from an informal pre-listing indication.

Why should investors treat IPO GMPs cautiously?

Investors should treat IPO GMPs cautiously because they are unofficial market indications, not assured listing-price forecasts. The social-media discussion itself notes that the implied gain in BLS Polymers was not guaranteed, while the recent listings show positive and negative outcomes across the same period.

A listing scoreboard covering 13 IPOs over the previous 30 days said the grey market did not correctly predict the direction of any of those listings. The underlying examples include Vedant Poly Fabs, which was shown at Rs 89.3 on listing against its Rs 94 issue price, and Zetwerk Manufacturing Businesses, which listed at Rs 138.25 against an issue price of Rs 151. Retail participants therefore need to distinguish between an unofficial premium and the final exchange-traded price.

Conclusion

India IPO grey market premiums currently present a mixed picture rather than a single market-wide signal. National Stock Exchange of India’s nearly 32% GMP decline stands alongside positive indications for Crystal Crop Protection and BLS Polymers, while recent listing outcomes range from strong gains to losses below the issue price.

The next event to watch is Crystal Crop Protection’s IPO opening on November 18 at its Rs 259-272 price band. Investors will also watch whether its reported 16-18% grey-market indication holds closer to the issue and whether actual listing performance follows the uneven pattern seen in recent IPOs.